ArticleBMC endocrine disorders2026
Serum adiponectin and soluble intercellular adhesion molecule-1 in patients with diabetic foot ulcers: a retrospective cohort study on the evaluation of disease severity and prognosis.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveThis study assessed serum Adiponectin (APN) and Soluble Intercellular Adhesion Molecule-1 (sICAM-1) levels in diabetic foot ulcer (DFU) patients for evaluating disease severity and prognosis.
methodsIn this retrospective cohort study, 92 DFU patients were assessed during a 6-month outcome evaluation period and categorized by ulcer healing into good prognosis (healed, n = 50) or poor prognosis (unhealed, n = 42). Serum APN and sICAM-1 levels were measured by Enzyme-Linked Immunosorbent Assay (ELISA) and and analyzed for correlations with disease severity and infection grades. Receiver Operating Characteristic (ROC) curves evaluated their predictive value for poor prognosis.
resultsSerum APN was negatively correlated with infection and disease severity, whereas sICAM-1 exhibited a positive correlation. The good prognosis group had significantly higher APN and lower sICAM-1 levels compared to the poor prognosis group. Both biomarkers predicted poor prognosis: APN (Area Under the Curve (AUC) = 0.765), sICAM-1 (AUC = 0.841). Combining both markers yielded an AUC of 0.853.
conclusionSerum APN and sICAM-1 levels are associated with DFU severity and prognosis, supporting their potential as predictive biomarkers in clinical practice. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.